Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Amedisys Inc. (NASDAQ: AMED) shares increased 1.09 percent to close at $14.89 a share Monday. The stock traded between $14.67 and $15.11 on volume of 218,665 shares traded. The company announced that it plans to close 29 care centers and to consolidate another 25. Shares of Amedisys are up approximately 2.0 percent year-to-date.
Get more information on Amedisys and free access to the in-depth equity report at: www.FiveStarEquities.com/AMED
BioFuel Energy Corp. (NASDAQ: BIOF) shares skyrocketed 132.48 percent to close at $7.30 a share Monday. The stock traded between $4.00 and $7.80 on volume of 18.08 million shares traded. The company announced that it has received a preliminary non-binding proposal from Greenlight Capital, Inc. for a possible transaction. Shares of BioFuel Energy have gained over 300.0 percent year-to-date.
Get more information on BioFuel Energy and free access to the in-depth equity report at: www.FiveStarEquities.com/BIOF
Edwards Lifesciences Corp. (NYSE: EW) shares spiked 4.23 percent to close at $74.17 a share Monday. The stock traded between $72.04 and $75.62 on volume 4.05 million shares traded. A recent report presented at the American College of Cardiology showed that the company's Sapien XT valve outperformed Medtronic Inc.'s device in a head-to-head comparison. Shares of Edwards Lifesciences are up approximately 13.0 percent year-to-date.
Get more information on Edwards Lifesciences free access to the in-depth equity report at: www.FiveStarEquities.com/EW
Prana Biotechnology Limited (NASDAQ: PRAN) shares plunged 71.60percent to close at $2.80 a share Monday. The stock traded between $2.78 and $3.24 on volume 23.63 million shares traded. The company announced that its Alzheimer's treatment, PBT2, failed to meet its primary endpoint in a recent trial. Shares of Prana Biotechnology are down approximately 60.0 percent year-to-date.
Get more information on Prana Biotechnology and free access to the in-depth equity report at: www.FiveStarEquities.com/PRAN
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]